文献速递重症综合管理与镇静镇痛

重症医学科医师配置与ICU死亡率及成本效益的日本全国观察性研究

Intensive care unit mortality and cost-effectiveness associated with intensivist staffing: a Japanese nationwide observational study.
PubMed 文献 · J Intensive Care · 2023-12-04
一句话结论日本全国数据显示,高配置ICU(ICU1/2)较低配置ICU(ICU3/4)ICU死亡率更低(2.6% vs 4.3%),且具成本效益(ICER 718,659日元/QALY)。

该回顾性观察研究利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者,按每日收费类别分为高配置ICU(ICU1/2,n=71,412)和低配置ICU(ICU3/4,n=46,330)两组。结果显示,ICU1/2组ICU死亡率2.6%低于ICU3/4组4.3%(p<0.001),院内死亡率6.1%低于8.9%(p<0.001)。ICU1/2组人均费用2,249,270±1,955,953日元,高于ICU3/4组的1,682,546±1,588,928日元,差值为566,724日元。增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。结论认为ICU1/2与更低的ICU患者死亡率相关,且治疗较ICU3/4更具成本效益。

要点

  • 高配置ICU(ICU1/2)组ICU死亡率为2.6%,低配置ICU(ICU3/4)组为4.3%,差异有统计学意义(p<0.001)。
  • 高配置ICU(ICU1/2)组院内死亡率为6.1%,低配置ICU(ICU3/4)组为8.9%,差异有统计学意义(p<0.001)。
  • 高配置ICU(ICU1/2)组人均费用为2,249,270±1,955,953日元,低配置ICU(ICU3/4)组为1,682,546±1,588,928日元,差值为566,724日元。
  • 增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。
  • 该研究为回顾性观察性研究,利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者。

适用人群与场景

  • 2020年4月至2021年3月入住日本ICU的患者,分为ICU1/2组(n=71,412;60.7%)和ICU3/4组(n=46,330;39.3%)。

诊断标准与关键阈值

  • 日本ICU按每日管理费分为四类:ICU管理费1和2(ICU1/2,相当于高配置)与3和4(ICU3/4,相当于低配置)。

研究设计与关键结果

  • 研究类型:回顾性观察性研究,利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者。
  • 主要终点:ICU死亡率ICU1/2组2.6% vs ICU3/4组4.3%(p<0.001);院内死亡率ICU1/2组6.1% vs ICU3/4组8.9%(p<0.001)。
  • 成本:人均费用ICU1/2组2,249,270±1,955,953日元 vs ICU3/4组1,682,546±1,588,928日元,差值566,724日元。
  • 增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。

证据类型、等级与局限

  • 证据类型:回顾性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:ICU1/2与更低的ICU患者死亡率相关,且治疗较ICU3/4更具成本效益(ICER<500万日元/QALY)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Japan has four types of intensive care units (ICUs) that are divided into two categories according to the management fee charged per day: ICU management fees 1 and 2 (ICU1/2) (equivalent to high-intensity staffing) and 3 and 4 (ICU3/4) (equivalent to low-intensity staffing). Although ICU1/2 charges a higher rate than ICU3/4, no cost-effectiveness analysis has been performed for ICU1/2. This study evaluated the clinical outcomes and cost-effectiveness of ICU1/2 compared with those of ICU3/4.

METHODS: This retrospective observational study used a nationwide Japanese administrative database to identify patients admitted to ICUs between April 2020 and March 2021 and divided them into the ICU1/2 and ICU3/4 groups. The ICU mortality rates and in-hospital mortality rates were determined, and the incremental cost-effectiveness ratio (ICER) (Japanese Yen (JPY)/QALY), defined as the difference between quality-adjusted life year (QALY) and medical costs, was compared between ICU1/2 and ICU3/4. Data analysis was performed using the Chi-squared test; an ICER of < 5 million JPY/QALY was considered cost-effective.

RESULTS: The ICU1/2 group (n = 71,412; 60.7%) had lower ICU mortality rates (ICU 1/2: 2.6% vs. ICU 3/4: 4.3%, p < 0.001) and lower in-hospital mortality rates (ICU 1/2: 6.1% vs. ICU 3/4: 8.9%, p < 0.001) than the ICU3/4 group (n = 46,330; 39.3%). The average cost per patient of ICU1/2 and ICU3/4 was 2,249,270 ± 1,955,953 JPY and 1,682,546 ± 1,588,928 JPY, respectively, with a difference of 566,724. The ICER was 718,659 JPY/QALY, which was below the cost-effectiveness threshold.

CONCLUSIONS: ICU1/2 is associated with lower ICU patient mortality than ICU3/4. Treatments under ICU1/2 are more cost-effective than those under ICU3/4, with an ICER of < 5 million JPY/QALY.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Ikumi S, Shiga T, Ueda T, et al. Intensive care unit mortality and cost-effectiveness associated with intensivist staffing: a Japanese nationwide observational study. J Intensive Care. 2023. PMID: 38049894. doi:10.1186/s40560-023-00708-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。